Abstract
Polygenic risk scores (PRSs) are typically validated using population-level metrics, masking variability in individual-level risk prediction and hindering clinical translation. To address this, we introduced a novel framework using a “benchmark” cohort (N=1184) of “unexpected coronary artery disease (CAD)”: early-onset patients (<55 years) with a clinical profile—low 10-year risk, no diabetes or severe hypercholesterolemia—that excludes therapy indications. The occurrence of early CAD in these clinically low-risk individuals establishes a “ground truth” for high genetic risk. We evaluated 58 published CAD PRSs and demonstrated a disconnection between population-level performance and individual-level accuracy (proportion of benchmark patients captured). The proportion captured by 58 PRSs varied from 10.8% to 33.1%, and the top-performing score was 2-fold more effective at identifying the benchmark group than established non-genetic biomarkers, such as lipoprotein(a). Furthermore, benchmark patients never captured by any score exhibited significantly healthier lipid profiles. Our framework provides an essential method for validating clinical readiness of PRSs.
Competing Interest Statement
Dr. Fahed is co-founder of Goodpath and Avigena; has served as scientific advisor to MyOme, HeartFlow, Aditum Bio and Arboretum; and has received a research grant from Foresite Labs and Sarepta Therapeutics, all unrelated to the present work. Dr. Honigberg has received consulting fees from Comanche Biopharma; has served on an advisory board for Miga Health; has done site principal investigator work for Novartis; and has received research support from Genentech, all unrelated to the present work, all unrelated to the present work. Dr. Natarajan reports research grants from Allelica, Amgen, Apple, Boston Scientific, Cleerly, Genentech / Roche, Ionis, Novartis, and Silence Therapeutics, personal fees from AIRNA, Allelica, Apple, AstraZeneca, Bain Capital, Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech / Roche, GV, HeartFlow, Incyte, Magnet Biomedicine, Merck, Novartis, Novo Nordisk, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, and TenSixteen Bio, royalties from Recora for intensive cardiac rehabilitation, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. Dr. Sui reports serving as a consultant for Arboretum Lifesciences, unrelated to the present work. Dr Paruchuri reported grants from Allelica, Amgen, AstraZeneca, Genentech, Ionis Pharmaceuticals, Novartis, and NewAmsterdam Pharma and personal fees from NewAmsterdam Pharm, all unrelated to the present work. Dr. Chan served as a consultant for Pfizer Inc. and Boehringer Ingelheim, all unrelated to the present work. The other authors declare no competing interests.
Funding Statement
All UKB analyses were performed under application no. 7089. Dr. Yu is supported by R00(HG012956) from National Human Genome Research Institute and Early Career Investigator Award (18CVD04) from Foundation Leducq Clonal Hematopoiesis and Atherosclerosis Network. Dr. Fahed is supported by grants K08HL161448 and R01HL164629 from the National Heart, Lung, and Blood Institute. Dr. Sui is supported by the TOPMed fellowship from the National Heart Lung and Blood Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Massachusetts General Hospital Institutional Review Board (protocol 2021P002228) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
